

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On November 4, the Board of Directors (the “Board”) of China Biologic Products, Inc. (the “Company”) appointed Mr. David Li as a director of the Company, effective from the same date thereof.

Mr. David Li has served as a Managing Director of Warburg Pincus Asia LLC (“Warburg Pincus”) since 2002. Mr. David Li is responsible for Warburg Pincus’ investment activities in China. Prior to joining Warburg Pincus, Mr. Li served as an executive director in the investment banking division of Goldman Sachs from 2001 to 2002 and that of Morgan Stanley from 1994 to 2001. He is also a director of China Auto Rental Holdings, China Kidswant Investment Holdings Co., Ltd, Cubic City (China) Service Apartment Group, D. Tong Insurance Sales & Service and Synutra International. Mr. Li received a B.S. in economics from Renmin University of China and an M.B.A. from Yale University School of Management.

The Company has entered into a Director Agreement and an Indemnification Agreement with Mr. Li on November 7, 2013. At Mr. Li’s request, he will receive no compensation for his service as a director of the Company, under the terms of the Director Agreement. Under the terms of the Indemnification Agreement, the Company agreed to indemnify Mr. Li against expenses, judgments, fines, penalties, or other amounts actually and reasonably incurred by him in connection with any proceeding, provided that he has acted in good faith and in the best interests of the Company. The description of the terms of the Director Agreement is qualified in its entirety by the provisions of the Director Agreement filed as an exhibit to this Current Report on Form 8-K. The description of the terms of the Indemnification Agreement herein is qualified by reference to the provisions of the Indemnification Agreement, the forms of which was filed as an exhibit to the Company’s Form 8-K filed on July 30, 2008.

There is no family relationship between Mr. Li and any directors or executive officers of the Company. In addition, there has been no transaction, nor is there any currently proposed transaction, between Mr. Li and the Company that would require disclosure under Item 404(a) of Regulation S-K.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit Number Description

10.1 Director Agreement between David Li and China Biologic Products, Inc., dated November 7, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 8, 2013 CHINA BIOLOGIC
PRODUCTS, INC.

By: /s/ David (Xiaoying) Gao
David (Xiaoying) Gao
Chief Executive Officer